Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

CME Group (CME): which funds own it

Financials →Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow CME for free
Share

Sections with a free account

29 concentrated managers hold it with a median weight of 2.1%.

Who owns CME Group?

Holders that filed a Schedule 13D or 13G with the SEC for owning more than 5% of the shares: Vanguard Capital Management (13G filed Apr 29, 2026). As of Jun 30, 2026, the largest holders reported on Form 13F were BlackRock (30.6 million shares), Vanguard Capital Management (23.7 million shares) and State Street (16.3 million shares).

Which institutions hold the most CME Group shares?

Per Form 13F filings as of Jun 30, 2026:

  1. 1. BlackRock: 30.6 million shares
  2. 2. Vanguard Capital Management: 23.7 million shares
  3. 3. State Street: 16.3 million shares
  4. 4. Morgan Stanley: 9.7 million shares
  5. 5. Geode Capital Management: 9.3 million shares
  6. 6. Vanguard Portfolio Management: 9.2 million shares
  7. 7. Capital World Investors: 6.8 million shares
  8. 8. JPMorgan Chase: 5.8 million shares
  9. 9. Sanders Capital: 5.1 million shares
  10. 10. Norges Bank: 4.8 million shares

Sources:13G by Vanguard Capital Management (Apr 29, 2026) ↗All of the company's proxy statements on EDGAR ↗

With more than one share class, a 13D or 13G counts shares convertible from another class as owned, so we do not show its percentage. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

CME Group revenue

CME Group reported annual revenue of $6.52 billion for fiscal year 2025 (year ended December 31, 2025), according to its Form 10-K filed with the SEC (XBRL data).

Well-known investors holding it

Seth Klarman 13F (Q2 2026)George Soros 13F (Q2 2026)Tom Gayner 13F (Q2 2026)Andreas Halvorsen 13F (Q2 2026)

Concentrated managers
29
All 13F: 1,712
Consensus
27/100
across 29 concentrated managersRanks by accumulation, portfolio weight and number of managers; it does not say more are buying than selling.
Price at Jun 30, 2026 (per 13F)
$220.83
-25.2% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (29 → 29): 3 opened · 3 exited = 0

Net flow in the quarter: −$379M (−1.7 M shares) · bought $512M and sold $891MShares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

The set of concentrated managers changed between quarters: with the set as it was then, 30 held it last quarter (the chart point); with today's set, 29 (the base for the change).

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Other relevant holders

Filers with $100M or more in the stock that do not count as concentrated managers because of their type: they are left out of the counts, the consensus and the accumulation.

Largest holders of CME (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Fundamentals

12-month figures to Sep 30, 2026.

Profitability
Operating margin
65.7%
Net margin
63.3%
ROE
16.6%
Growth
Revenue (TTM)
$7.0 bn
Revenue growth
9.0%
Net income (TTM)
$4.4 bn
Balance sheet
Quality vs sector
64/100

Bank, insurer or other financial company: we do not show net debt / EBITDA or free cash flow. Its cash flow moves with loans and the investment portfolio, and its debt is part of the business: those figures do not read as they do for an industrial company.

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Shares outstanding: buybacks and dilution

Diluted shares by fiscal year (split-adjusted)

2025: 360.3 M

360.3 M0
20162025
1 year
+0.1%
3 years
+0.3%
5 years
+0.5%
Buybacks (FY 2025)
no data
Share issuance
no data
Stock-based compensation
$94.8M1.5% of revenue
Dividends paid
$3.9 bn

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
1.00

Bank or insurer: debt ratios do not apply.

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
0
Amount (6 m)
$0
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Sep 9, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

    «CME Group Announces New Senior Leadership Appointments»

  • Jun 17, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

    «CME Group Terry Duffy Will Step Down as Chief Executive Officer and Transition to Executive Chairman of the Board in March 2027; President and CFO Lynne…»

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Financials stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Financials →

Follow CME for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow CME